Why is compounded semaglutide "going away"? (FDA shortage-list status explained)

What a shortage listing allowed

When a drug is on FDA’s shortage list, federal compounding rules can allow certain activity that would otherwise encounter the restrictions on copies or bulk substances. FDA’s shortage-compounding explanation makes the allowance conditional rather than automatic. The listing matters because it changes the regulatory circumstances, not because a compounded version becomes FDA-approved while the shortage lasts. Approval status and shortage-related exemptions are separate questions. [2][3]

This distinction helps explain why companies could advertise broadly during a shortage and later change or withdraw an offer. The regulatory basis for a category of activity can change even if a signup process or price page looks the same. A reader needs the dated FDA status and the actual preparation’s pathway. An old provider page is evidence of an advertisement at that time, not a permanent authorization for future pharmacy transactions. [2]

The February 2025 decision and the following updates

FDA announced semaglutide injection shortage resolution on February 21, 2025. The same chronology initially described separate transition periods for state-licensed pharmacies or physicians under 503A and for outsourcing facilities under 503B. Later updates addressed litigation and enforcement timing. Read the dated entries together instead of extracting one early deadline as the entire current rule. [1]

The agency’s April 28, 2025 update says the 503A enforcement-discretion period had ended following the court decision and described the 503B window through May 22, 2025. Those historical dates explain the change in broad shortage-era access. They should not be used to claim a fresh transition period in October 2026 or to certify a provider’s current operation. The newest policy reminder supplies the current conditions summarized in this guide. [1]

What remains possible is a different question

FDA’s April 2026 reminder describes patient-specific 503A compounding and the restrictions on essentially copies of commercial drugs, including a documented significant difference for an identified patient. That conditional framework is different from routinely selling a commercial copy under an ongoing national shortage exception. The prescriber and pharmacy must assess the actual preparation and requirements; this publisher does not supply that assessment. [1]

For 503B outsourcing facilities, the reminder separately addresses bulk-substance eligibility. It says semaglutide and tirzepatide are not currently on the 503B bulks list or shortage list. Registration of a facility is not the same as inclusion of an ingredient on that list. A source about one category should not be used to infer permission under the other. [1][4]

A local stock problem is not the national listing

FDA describes shortage resolution in terms of national supply and projected demand. Its announcement also recognizes that localized supply disruptions can still occur as products move through the distribution chain. A patient unable to locate a particular package therefore has an important practical access problem, but that alone does not restore the drug’s national shortage status or the old compounding exception. [5][1]

Ask the care team and pharmacy about the current prescription and fulfillment options for that specific situation. Do not treat an unavailable package at one store as evidence that every advertised compounded preparation is now permissible. Our state and medication directories describe recorded provider access; neither functions as a live pharmacy-inventory system or changes the official shortage list. [6][2]

Why additives and new plan names do not settle the change

Some marketing emphasizes a personalized formulation or an added ingredient. FDA’s current reminder discusses how products containing additional active ingredients can still fall within its essentially-copy analysis, including a B12 example. The presence of an additive is not automatic proof that the old restriction has been avoided. The applicable clinical documentation and other conditions concern the specific preparation and patient. [1]

A renamed subscription or a different billing term also does not change the compounding pathway. Prices and commitments are financial facts, while approval and compounding conditions are regulatory facts. Our cost comparison can explain the former without certifying the latter. Keep the medication description and pharmacy identity beside the quote when discussing a provider’s revised offer. [3][7]

How to read current access claims

Check the date on the source, whether it describes a shortage-era window or current policy, and whether the claim concerns a 503A prescription or a 503B facility. A page quoting a past FDA announcement can be accurate history and still be insufficient support for today’s availability. Ask the actual prescribing and dispensing organizations to confirm their arrangement rather than treating the continued existence of a website as a regulatory status check. [1][8]

Also keep proposals distinct from final actions. FDA’s April 2026 GLP-1 bulks-list announcement describes a proposal. This guide does not present it as a final rule or infer a new blanket ban from it. The verified current policy is enough to explain why routine shortage-based copying is different from the remaining conditional framework. If the official rules change, their new terms need a fresh check before publication claims are updated. [9][4]

The headline does not mean semaglutide as an ingredient disappeared

Going away in this context describes changes to shortage-based compounded access, not cancellation of every approved semaglutide product’s identity. Manufacturer sources still distinguish their branded pharmacy products and current terms. The ingredient, an approved brand’s finished preparation and the legal basis for a compounder’s activity are three separate subjects. If a provider changes its program after shortage resolution, ask what product it now offers. Do not assume the historical headline says that semaglutide itself has been removed from all prescribing or that every pharmacy must follow an identical contractual change. [10][11][1]